Sutro Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Sutro Biopharma, Inc. (Nasdaq: STRO) on August 12, 2024, covering events occurring on August 8, 2024. The filing addresses corporate governance changes specifically regarding the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Sukhi Jagpal to the Board of Directors. Key details include:
- Role: Appointed as a Class III director effective August 8, 2024, and as a member of the Audit Committee effective August 15, 2024.
- Cash Compensation: Mr. Jagpal will receive a pro rata portion of the $40,000 annual director retainer and a pro rata portion of the $10,000 annual Audit Committee retainer for the remainder of the year.
- Equity Compensation:
- Stock option to purchase 35,000 shares, vesting monthly over three years.
- Stock option to purchase 28,959 shares, vesting monthly until the 2025 annual meeting of shareholders.
- Exercise Price: Both options have an exercise price equal to the closing sale price of the common stock on August 8, 2024.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It confirms that there are no undisclosed arrangements regarding Mr. Jagpal's selection and no family relationships with other directors or officers.
Investor Verification Checklist
- Verify the closing stock price on August 8, 2024, to determine the exercise price of the granted options.
- Review the Company's existing compensation policy for non-employee directors to confirm the pro rata calculation methodology.
- Confirm the vesting schedule details for the 28,959 shares tied to the 2025 annual meeting.
- Check subsequent filings for any changes to the Audit Committee composition effective August 15, 2024.